NOTIFY (New Observations Taking Information From Yesterday)

Launched by STANFORD UNIVERSITY · Jul 28, 2023

Keywords

ClinConnect Summary

The NOTIFY trial is studying whether informing patients and their doctors about a specific finding on a low-dose CT scan—called coronary artery calcium—can help prevent serious heart-related problems, like heart attacks or strokes. This trial is focused on individuals who have undergone a lung cancer screening with this type of scan and have a moderate to high level of calcium buildup in their coronary arteries, which may indicate a higher risk for heart issues. The goal is to see if this kind of notification leads to better health outcomes compared to standard reminders for doctors.

To be eligible for the trial, participants need to be at least 18 years old, have no known history of heart disease, and have had a lung cancer screening in the last five years that showed a high coronary artery calcium score. They should not be currently taking any cholesterol-lowering medications. If someone decides to join the trial, they can expect to be monitored closely and receive tailored guidance based on their health needs. This study is not yet recruiting participants, but it could provide valuable insights into improving heart health for people at risk.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age \>=18 years
• • No known ASCVD
• • Lung cancer screenee with low dose CT scan (LDCT) within the last 5 years
• • Coronary artery calcium (CAC) score on LDCT \>100 Agatston units (AU)
• • Not taking a statin or other lipid-lowering therapy (e.g., ezetimibe, bempedoic acid, or PCSK9-lowering therapy)
• Exclusion Criteria:
• • Dementia or other neuropsychiatric disorder that interferes with medication adherence
• • CAC scan, coronary CT angiogram, or invasive angiogram since LDCT
• • Statin medication intolerance or allergy
• • Life expectancy \<2 years, e.g., metastatic cancer or active cancer undergoing chemotherapy